The EVI1 gene is a transcriptional regulator of hematopoietic stem cell self renewal and its overexpression is associated with adverse prognosis in de novo AML. Whether the overexpression of EVI1 also predicts poor outcome of AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first CR (CR1) is still unclear. Thirty-two (21.2%) out of 151 patients were categorized as high EVI1 expression (EVI1+), and 119 (78.8%) patients were categorized as low EVI1 expression (EVI1 − ). The frequency of EVI1+ was much higher in the adverse-risk group than the intermediate-risk group (53% vs 19%, P = 0.005). EVI1+ patients were significantly likely to harbor with translocations involving the MLL gene on 11q23 (8/9). Significantly poor results were observed in the EVI1+ cohort in terms of leukemia-free survival (LFS) (in 24 months 52.6 vs 71.0%, P = 0.027), overall survival (OS) (in 24 months 52.8 vs 72.4%, P = 0.012), and cumulative incidence of relapse (in 24 months 39.5 vs 22.5%, P = 0.013). Multivariable analysis revealed that low EVI1 expression as an independent prognostic factor favoring LFS (hazards ratio = 0.47, 95% confidence interval 0.26-0.86, P = 0.01) but not OS. Our results indicate high EVI1 expression might predict high risk of relapse in AML patients undergoing myeloablative allo-HSCT in CR1.
INTRODUCTION
Ecotropic virus integration site 1 (EVI1) gene (also named MECOM gene) is located on chromosome 3q26, encoding a zinc-finger protein that functions as a transcriptional regulator of hematopoietic stem cell self renewal and long-term multilineage repopulating activity. [1] [2] [3] EVI1 overexpression (EVI1+) has been reported in up to 8% of patients with de novo AML and is associated with an adverse prognosis. 4, 5 In AML carrying the chromosome abnormalities of inv(3)(q21q26.2) or t(3;3)(q21; q26.2), aberrant EVI1 expression is caused by a distal GATA2 enhancer. 6, 7 In addition to the classical 3q26 translocation, elevated EVI1 expression is also observed in cryptic 3q26 rearrangements. 8 However, EVI1+ was also found in AML patients without chromosome rearrangements involving 3q26/EVI1 locus. Reports have indicated significant association of EVI1+ to chromosome abnormalities monosomy 7 and t(11q23) (or MLL rearrangement) in AML, predicting poor outcome. [9] [10] [11] Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still known to be the only curative treatment for AML patients with unfavorable features. 12 Myeloablative conditioning (MAC) regimens may reduce relapse of high-risk hematological malignancies and promote disease-free survival through significant reduction of leukemia residual disease. 13 However, clinical and prognostic significance of EVI1+ in AML patients receiving allo-HSCT after MAC has not been clearly identified. Here, we retrospectively examined EVI1 expression levels and clinical outcomes in 151 de novo AML patients treated with myeloablative allo-HSCT.
PATIENTS AND METHODS Patients
From January 2008 to December 2014, a total of 151 de novo AML patients undergoing myeloablative allo-HSCT were included in present retrospective study. Diagnosis and classification of AML were defined according to FAB classification and revised with application of the World Health Organization (WHO 2008) classification. Only patients achieving CR after one course of standard 3 day anthracyclines plus 7 days cytarabine induction regimen were included into our study. Selected CR patients were allocated to intermediate-risk or adverse-risk groups according to the NCCN risk stratification criteria 14 of AML and selectively assigned to different MAC allo-HSCT (donors from related or unrelated, grafts from mobilized bone marrow, peripheral blood or umbilical blood cord) depending upon available donors and other individual factors. All the specimen of bone marrow from patients before their induction therapy were collected and analyzed for EVI1 expression by RQ-PCR, cytogenetic analysis through standard R-binding technique, mutation status analysis in Internal tandem duplications of FLT3 (FLT3-ITD), tyrosine kinase domain of FLT3 (FLT3-TKD), NPM1, CKIT, CEBPA and DNMT3A by Sanger sequencing. All recipients were examined for high-resolution HLA typing at A, B, Cw, DR and DQ alleles. The corresponding donors/umbilical blood cords were tested or rechecked for HLA typing (low-resolution HLA typing at A, B, DR alleles for related donors/umbilical blood cords and high for unrelated donors). Diseases progression and survival status of patients after allo-HSCT were surveyed. This study was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University following Declaration of Helsinki conditions. Sample preservation and genetic analysis required informed consent, which was obtained accordingly. /day for days +3,+6 and +11) as aGvHD prophylaxis. Patients undergoing HSCT from haplo-identical related donors or unrelated donors or umbilical blood cord received GvHD prophylactic treatment with CsA (2.5-3 mg/kg/day from days − 9 to 30, then tapering), MTX (same as HLA-identical sibling transplantation), mycophenolate mofetil (MMF, 1.0 twice a day, days − 10 to +30, then tapering), and rabbit antithymocyte globulin (r-ATG, Genzyme, Cambridge, MA, USA, 2.5 mg/kg/day for days − 5 to − 2). Mobilization, collection and infusion of HSCs were carried out according to our center's protocols as previously described. 9, 15, 16 RQ-PCR RNA extraction and RQ-PCR to measure EVI1 expression levels are described in the Supplementary Appendix. An absolute RQ-PCR measurement of EVI1 was applied. The mean value of EVI1 in 12 normal controls was 12.00% (SE = 12.67%, EVI1 over housekeeping gene) and was considered as baseline. A cutoff analysis of EVI1 was determined according to the method of Groschel S in his Supplementary Material. 9 EVI1 expression levels were dichotomized based on a cutoff value of 10 times over the baseline. Thirty-two patients were defined as EVI1+ and the remainder EVI1 − .
Definition of and Post-transplantation evaluations
Successful neutrophil engraftment was defined as the first day of consecutive ANC over 500/μL for 3 days; platelet engraftment was defined as the first day of consecutive platelet count over 20 000/μL for 7 days without transfusion support. Graft failure was defined as failure to achieve neutrophil engraftment until day +100 post transplantation. Disease relapse was defined as the recurrence of AML matching the clinical and pathological criteria. 17 OS was measured from the date of HSCT until date of death, regardless of cause. Leukemia-free survival (LFS) was measured from the date of HSCT until the date of relapse or death, regardless of cause; patients alive at the last follow-up were censored. 18 Acute GvHD was scored on the criteria of MDACC. 19 
Statistical analysis
Correlations between different expression of EVI1 and characteristics of baseline demographic, clinical, cytogenetic, molecular features and transplantation subtype distributions were calculated using Wilcoxon rank-sum test (continuous variables) and the Χ 2 -test or Fisher exact test (categorical variables). OS and LFS were calculated using the Kaplan-Meier method and the log-rank test. For cumulative incidence of relapse rate after allo-HSCT, mortality without relapse was considered as completing risk factor and Gray's test was applied. Cox proportional hazards regression models were constructed for OS and LFS to assess the impact of different EVI1 levels when controlling for other prognostic variables. Variable selection was done by univariate analysis to identify those variables with significant level α o0.2. These variables included patients' age (stratified by decade), gender, white blood cell count (log10), percentage of blasts in bone marrow, cytogenetic-risk category, genetic mutations (or NCCN 2014 AML risk stratification criterion (instead of cytogenetic and mutation)), EVI1 expression status, conditioning regimen, related or unrelated donors, full-matched or partial matched grafts. Multivariable analysis used stepwise selection based on P-value. Estimates for hazard ratios and corresponding 95% confidence intervals (CIs) were obtained for each significant prognostic factor. A graphic user-interfaced EZR software (version 1.25) based on R program (version 3.1.1) was used for statistics. 20 
RESULTS
Characteristics and outcome of patients undergoing myeloablative allo-HSCT A total of 17.9% (n = 27) of patients had full-matched unrelated donor, while 5.3% (n = 8) of patients underwent unrelated allo-HSCT from one or two allelic sub-locus mismatched donor. Haplo-identical related transplantation recipients accounted for 23.8% (n = 36); and matched sibling transplantation recipients accounted for 47.7% (n = 72). A total of 22.5% (n = 34) of patients received bone marrow-derived HSCs; 49.7% (n = 75) of patients were transplanted with peripheral blood HSCs; 23.2% (n = 35) of patients were transplanted with bone marrow stem cells on day 0 and peripheral blood HSCs on the following day, while umbilical cord blood HSCs were used in 4.6% (n = 7) patients. Eleven patients received mTBI/CY conditioning regimen, whereas 140 patients received mBU/CY conditioning regimen. No significant difference (P = 0.800) was observed in the proportion of conditioning regimen enrollment between EVI1+ and EVI1 − patients. Difference in the proportion of related or unrelated donors was not significant as well (P = 0.398). But with respect to the source of HSCs, proportion of EVI1+ patients transplanted with bone marrow+peripheral blood HSC increased significantly (P = 0.002). More EVI1+ patients received HLA mismatched donor transplantation (50 vs 29%, P = 0.022). Transplantation was successful in all patients, with a median neutrophil recovery time of 13 days (10-20 days), and a median platelet recovery time of 17 days (11-180 days). All patients had full chimerism (495%) within 1 month after transplantation. The 100 day cumulative incidence of aGvHD (grades II-IV) was 21% ± 5%, of which severe aGvHD (grades III-IV) was found in seven patients. After treatment, aGvHD was under control in four patients, while the other three patients died of severe secondary infection (one case of sepsis and two cases of pneumonia). Two-year cumulative incidence of cGvHD was 30% ± 10%, with 15 patients developing into extensive cGvHD. Among them, six patients died of respiratory or liver failure. Furthermore, 43 patients died of leukemia relapse; and 21 patients died of non-relapse causes, of which one died of posttransplant lymphoproliferative disorder. Cumulative incidence of transplantation related mortality of 24 months was 9.6% (95% CI, 2.4-23.1%) for EVI1+ patients and 11.8% (95% CI, 6.6-18.7%) for EVI1-ones.
Clinical characteristics of different EVI1 expression levels EVI1 expression levels varied widely among all AML patients. Many patients had very low EVI1 levels, which were lower than or near the normal control levels. Among 151 patients, 32 patients (21.2%) had higher-than-cutoff values, constituting the EVI1 highexpression group, while the remaining 119 patients (78.8%) were included in the EVI1 low-expression group. The patients had a median age of 35 years (10-60 years), the majority of whom were males (59.6%). Comparison of clinical, laboratory and transplantation characteristics between the EVI1+ and EVI1 − groups is summarized in Table 1 . Distribution of EVI1 expression in different cytogenetic abnormality subgroups is shown in Supplementary  Figure S1 . No significant difference was found in age, gender and WBC count or marrow blast proportion between the two groups. In FAB classification, EVI1+ was more commonly seen in subtype M5, accounting for 44% (P = 0.0015). According to cytogenetic grouping, 11q23/MLL rearrangement anomalies were found in almost all EVI1+ patients, accounting for 88.9% (8/9), while found only in one EVI1 − patient, accounting for 11.1% (P o 0.0001). As for unfavorable karyotypes, -7/7q-was present in three patients in the EVI1 high-expression group, accounting for 9%, while in two patients in the low-expression group, accounting for 2%, showing a stronger trend in the EVI1 high-expression group (P = 0.0642). The study included only one patient with 3q26 abnormality and also high EVI1 expression. EVI1+ was rarely seen in normal Prognosis of EVI1 in AML undergoing allo-HSCT X He et al Abbreviations: BM = bone marrow; Cord = cord blood; FLT3-ITD = FLT3 internal tandem duplication; FLT3-TKD = FLT3 tyrosine kinase domain; PB = peripheral blood; WBC = white blood cell. P-value: The symbols in superscript '*' denotes rank-sum test and ' §' denotes Χ
-test.
Prognosis of EVI1 in AML undergoing allo-HSCT X He et al karyotype (19 vs 61%, P o 0.0001), and almost not seen in karyotypes t(8;21) and inv(16) of low-risk group with good prognosis. Overall, EVI1+ was more predominant amongst high cytogenetic-risk patients than low-and intermediate-risk patients (47% vs 13%, P o0.0001). With regard to frequent AML mutations, no significant difference was observed in FLT3-ITD, FLT3-TKD, c-KIT, NPM1, CEBPA or DNMT3A between the two groups. It should be noted that NPM1 mutation was found in only one patient in the EVI1+ group, whereas in 11 patients in the EVI1 − group. According to the NCCN AML risk stratification 2014 (combining cytogenetic and mutational characteristics), almost all transplantation recipients were at intermediate or high risk, and EVI1+ was more common among high-risk patients (P = 0.0005).
Prognostic impact of EVI1+ post myeloablative allo-HSCT We compared the survival between the two groups. Median follow-up time was 26 months (2-60 months) for all patients.
In the 24th month, OS was 52.8% (32.5-69.5%) in the EVI1 high-expression group, which was significantly lower than 72.4% (63-80%) in the low-expression group (P = 0.012). LFS was 52.6% (32.1-69.6%) in the EVI1 high-expression group, which was also significantly lower than 71.0% (61.4-78.5%) in the low-expression group (P = 0.027) (Figures 1a and b) . As a competitive factor, 24-month cumulative incidence of relapse was significantly higher for the EVI1 high-expression group 39.5% (20.9-57.6%) than the low-expression group 22.5% (15.2-30.7%) (P = 0.013) (Figure 1c After substituting the cytogenetic and mutational models with NCCN risk stratification in this model, the independent prognostic influence of EVI1 expression for LFS remained unchanged.
( Table 2 ). Considering that the high EVI1 expression accounted for 44% (14/32) in intermediate-risk karyotype, we performed additional survival analyses on intermediate-and high cytogenetic risk strata at different EVI1 expression levels. The results showed that after stratification, EVI1 expression had no significant effect on either LFS or OS. When the risk strata was replaced by NCCN risk stratification, EVI1 expression status also had no significant effect on LFS or OS in the intermediate-risk group; nevertheless, whereas high EVI1 expression exhibited an unfavorable prognostic trend (log-rank test, for OS, P = 0.13) (Supplementary Table S2 ).
DISCUSSION
We retrospectively analyzed the effects of EVI1 expression level on prognosis of MAC allo-HSCT recipients with AML in CR1. Our study enrolled CR1 patients aged 10-60 years who received transplantation, with inclusion of respective FAB subtypes, cytogenetic characteristics and molecular genetic characteristics, which are broadly representative. Our results demonstrate high EVI1 expression significantly correlated with unfavorable transplantation prognosis, indicating a high risk of leukemia relapse. We excluded patients unable to achieve CR after one course of chemotherapy, and therefore distribution of patients may be different from other studies. The total number of high EVI1 expression patients may also be less than that in other studies. This is due to poor first CR rate of all newly diagnosed EVI1+ AMLs in our center over the past 5 years to be 39.5%. Previous studies have indicated high EVI1 expression is often associated with some special genotypes, especially with unfavorable genetic characteristics, while rarely seen in favorable genetic changes. 9, 12 Among these studies, Groschel et al. 9 included 1382 newly diagnosed adult patients with AML younger than 60 years in joint analysis of two prospective multicenter trials of AMLSG and HOVON. Our study shows similar results. EVI1+ is more common among patients harboring high-risk genetic changes such as 11q23/MLL rearrangements and -7/7q-, while hardly seen in t(8;21), inv (16) or NPM1 mutated patients, and also rarely seen in normal karyotype patients. 4, 9 Mutations involving several leukemogenesis locus (such as FLT3-ITD, TET2, NPM1 and so on) are associated to outcome of AML and may correlate with distinct cytogenetic or gene expression abnormalities. We only screen five frequent mutated genes not including NRAS which are demonstrated to be associated with inv(3)/t(3;3) by some authors. 21, 22 However, the mutational landscape of EVI1+ AMLs should be revealed by next-generation sequencing targeting more genes frequently mutated in AML. Considering the low incidence of 3q26 rearrangement in all high EVI1 expression AMLs, no significant correlation is observed in these mutations despite the NPM1 mutation. A trend of negative association of NPM1 and EVI1 expression is observed in our study and Ho et al.'s study, whereas Groschel et al. show significant difference. 23, 22 In addition, in terms of morphology, we confirmed a higher incidence of EVI1+ in M5. Considering that EVI1+ is more commonly seen among high-risk patients, we performed allo-HSCT in the shortest possible time after remission. Thus, many patients were transfused with mobilized bone marrow and PBSCs using a recently mature related haplo-identical transplantation technique, which achieved good outcomes. [24] [25] [26] [27] Research on EVI1 focuses more on the comparison between allo-HSCT and non-transplantation consolidation therapy and drawing a firm conclusion that allo-HSCT significantly improves the prognosis of EVI1+ patients, while allo-HSCT alone is scantly studied. Even in the largest study by Groschel et al., only 28 patients with high EVI1 expression undergoing allo-HSCT were enrolled. Our study shows that in the 24 month, LFS and OS are more unfavorable in EVI1+ group, and cumulative incidence of relapse is also higher in the EVI1+ group, suggesting an adverse effect of EVI1+ on transplantation prognosis. Multivariate analysis incorporating initial diagnostic characteristics and transplantation characteristics reveals that EVI1 is an independent prognostic Abbreviations: CI = confidence interval; HR = hazards ratio; LFS = leukemia-free survival; OS = overall survival.
a Multivariable analysis after substitution cytogenetic and mutations with NCCN 2014 AML risk stratification.
Prognosis of EVI1 in AML undergoing allo-HSCT X He et al factor of LFS rather than OS. Discrepancy of OS and LFS may be that the subjects we included are patients in CR1 only. Patients who achieve CR after one course of standard induction therapy have higher chance of successful regaining of remission upon relapse, and prolonged survival accordingly for the sensitivity of cytotoxic drugs. As can be seen from our findings, in respect of effects on OS, ITD mutation and low cytogenetic risk are more influential than EVI1 expression, which become independent prognostic factors impacting OS. NCCN's AML risk stratification of 2014 integrates cytogenetic and mutational characteristics, which can better reflect the prognosis of AML. After replacing the cytogenetic risks and mutational characteristics with this stratification, it becomes an independent influencing factor of OS, which is confirmed in our study. Separate analysis on the prognostic effect of EVI1+ in intermediate-risk AML may be more conducive to determining the value of EVI1+ in transplantation prognosis. However, due to relatively small sample size, analysis we made in the Supplementary Material does not demonstrate significant effects of different EVI1 expression levels on prognosis. In the abovementioned studies, consensus is obtained of high EVI1 predicting unfavorable outcome in univariate analysis, while different results exist when multivariate models are constructed. Groschel et al. demonstrated high EVI1 expression predicted poor outcome for EFS, RFS but not OS. Ho et al. concluded EVI1 expression did not retain independent prognostic significance. 23 Another study by Barjesteh et al. prompted high EVI1-1d expression had a trend of difference of affecting outcome in multivariable analysis (P = 0.09) but showed significant difference in cohort of intermediate-risk karyotype. 4 The differences between these studies may be due to many factors including numbers of patients, variables into the model, and definition of the cutoff value. FLT3-ITD mutation strongly adversely affects the outcome of AML but was not included in the regression model by Groschel et al.
As for the important role of EVI1 expression in allo-HSCT outcomes, there is only one abstract published by Marius et al. in the 2013 American Society of Hematology Annual Meeting which summarizes the prognostic value of EVI1 in non-myeloablative conditioning allo-HSCT. 28 Researchers enrolled 57 AML patients with a median age 61 years (27-74 years). Their study is different from ours in that it did not exclude unremitted patients; besides, patients with high EVI1 expression accounted for 71.9%, which was significantly higher than 21.2% in our study. Univariate analysis showed that high EVI1 expression indicates shorter OS and EFS. And in subsequent multivariate analysis, high cytogenetic risk and high EVI1 expression exhibited unfavorable effects on OS (P = 0.12 and 0.14, respectively). Thirty-six-month OS was 40% in EVI1+ group. As the authors provided only the abstract, we can only speculate the causes of differences. First of all, the way cutoff values are defined may differ distinctly. Some studies defined all values higher than normal mean as EVI1+; we believe that such definition does not agree with the clinical features of high EVI1 expression. Owing to lower toxicity, RIC may bring the benefits of long-term survival while increasing the risk of relapse. 29 However, a growing number of recent studies support that RIC can provide an effect approximating GVL without increasing the relapse rate. [30] [31] [32] Our study, in comparison, includes more related haploidentical transplantation recipients, and achieves good outcomes as well. In our study, prognosis of high EVI1 expression patients is disappointing even after MAC allo-HSCT; additional regimen should be considered to combine with allo-HSCT. EVI1 is involved in epigenetic changes due to interaction with both the histone methyltransferase SUV39H1 and DNA methyltransferases DNMT3A and DNMT3B. 33, 34 Hypomethylating agents such as azacitidine and decitabine may improve the outcome of high EVI1 expression patients post allo-HSCT.
Thus, we can conclude that high EVI1 expression is more common in the M5 subtype, mostly for high cytogenetic risk group, and in 11q23 rearrangements while rarely seen in normal karyotypes. High EVI1 expression has a significant adverse effect on prognosis of MAC allo-HSCT recipients with AML in CR1, which is an independent prognostic factor of LFS rather than OS. In addition, it will be necessary to conduct multicenter co-operative studies to determine the effect of EVI1 expression on the outcome of AML in CR1 receiving allo-HSCT.
